Realbotix Pivots to Direct-to-Consumer, Banks on UBTECH Validation and a U.S. Ban
The $50M micro-cap resets its revenue narrative, launches a $12K tabletop robot, and eyes a NASDAQ RTO as it chases the mass-market AI companion wave.
XBOTF · Earnings Call · 2026-08-12
Reset and Reorientation
Realbotix Corp. (XBOTF) reported fiscal Q3 with a clear message: the revenue dip is a feature, not a bug. The holding company — home to B2B robotics unit Realbotix LLC and consumer intimacy brand AI companion unit Intima — used the call to walk investors through why quarterly sales look weak. CEO Andrew Kiguel blamed last year's clearance of a multi-year backlog and the deliberate exit from crypto staking. “When we get an order for a product, we do not record it as revenue until that product is shipped out... we're sort of into a more normal cycle” — Andrew Kiguel, CEO · 2026-08-12. The subtext: this is now a pure-play robotics business, but one still pre-revenue at scale.
The bigger story is a strategic pivot from bespoke, consultation-heavy B2B deployments to a direct-to-consumer, volume-oriented model. In September, Realbotix will launch a new line of life-like robots (two existing characters, two new), starting at $12,000 for a tabletop version and ~$55,000 for full-body, with a $250 deposit to hold a place in line. A subscription-based configuration app will let owners customize personality and AI — including integrating third-party models.
We're going to streamline the process of ordering the robots. We're lowering the price of the robots... with a view of moving into producing at scale in 2027.
Validation from an Unexpected Source
The most striking moment came when Kiguel framed a potential competitor as an accelerant. Chinese industrial-robotics firm UBTECH, which had visited Realbotix's booth at CES, recently launched a life-like humanoid line and sold over 13,000 units in ten days — roughly doubling the entire market's prior-year volume.
By essentially copying us, they doubled the size of the market... I estimate that's over $1 billion of revenue in 10 days. Why I like this is a couple of reasons. Number one, this validates what I've been saying for a long time.
That validation is amplified by the U.S. administration banning Chinese-made humanoid robots, leaving Realbotix as “the only game in town” for domestic life-like robots. The UBTECH episode is a double-edged sword: it proves demand, but also highlights how quickly a well-capitalized rival could imitate. For now, the tariff and policy shield provides a temporary moat.
Intima and the NVIDIA of Embodiment
Sue Ennis, President of Intima, framed the RealDoll brand as the physical bridge for the AI companion explosion — 680M monthly users globally, 35M in the U.S., and 28% reporting intimate relationships with AI. She argued RealDoll’s 30-year manufacturing history, customer base, and APIs position it as the infrastructure layer of embodied AI, drawing a direct analogy: “our ambition at RealDoll is to play a similar role enabling AI embodiment... building towards becoming the NVIDIA of AI embodiment” — Suzanne Ennis, President · 2026-08-12. This is a deliberate step up from the “doll” narrative, casting the business as a platform play.
NASDAQ, Media, and the Path Forward
Repeatedly, Kiguel returned to the pending ONCO transaction — a reverse merger that will list Realbotix LLC on the NASDAQ with a $125M valuation, where Realbotix retains 90%. The S-4 filing is expected within two weeks, with close in 2–4 months. “Being on the NASDAQ opens up the market. That's where we're going to get the best valuation... we're going to move the fundraising for that to this NASDAQ vehicle” — Andrew Kiguel, CEO · 2026-08-12. This is the same ambition he expressed a year ago, but now it has a concrete vehicle.
Media noise — particularly around the school deployment and privacy concerns — drew a sharp rebuke. Kiguel insisted the school deal remains on track, delayed “in the weeks, not in the months,” and accused the press of chasing clicks over truth. “Don't believe the media. Their agenda is not to necessarily to provide the truth… but to get clicks and rate” — Andrew Kiguel, CEO · 2026-08-12.
What Changed, and Why It Matters
Across the last five quarterly calls, the company has drifted from a custom, enterprise-first story (“we’re in conversations with large tech companies”) to a consumer-preorder model. The prior call (Aug-2025) already hinted at “when you’re trying to build a business... I can't always be worried about the bottom line” — Andrew Kiguel, CEO · 2025-08-14 and the path to lower-price robots by 2027–2028. That vision is now being executed, with a sharper competitive context.
The company is still sub-scale — revenue is negligible, and the burn is what it is — but the new product line, the NASDAQ vehicle, and the U.S. ban on Chinese rivals create a credible catalysts. If the $250-deposit pre-sale generates meaningful volume, the market could re-rate. If not, the story remains a high-risk option on embodied AI.
For now, Realbotix is a classic pre-revenue pivot play: a tiny company with a validated concept and a window of policy protection, betting that the consumer appetite for life-like companions is real and monetizable.